-
公开(公告)号：US10858415B2
公开(公告)日：2020-12-08
申请号：US15113981
申请日：2014-01-29
Applicant: BioNTech AG , TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg—Universitat Mainz gemeinnutzige GmbH , Universitatsmedizin der Johannes Gutenberg—Universitat Mainz , JPT Peptide Technologies GmbH
Inventor： Ugur Sahin , Matin Daneschdar , Hans-Ulrich Schmoldt , Laura-Marie Kring (née Plum) , Markus Fiedler , Ulf Reimer , Karsten Schnatbaum
IPC: A61K38/08 , A61K38/12 , C07K5/00 , A61K38/04 , C07K7/00 , C07K16/00 , C07K17/00 , C07K14/705 , C07K7/64 , A61K39/00 , G01N33/53 , G01N33/574
Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.
-
公开(公告)号：US10604568B2
公开(公告)日：2020-03-31
申请号：US14904011
申请日：2014-07-30
Applicant: BioNTech AG , Astellas Pharma Inc. , TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH
Inventor： Ugur Sahin , Ozlem Tureci , Korden Walter , Meike Wagner , Maria Kreuzberg , Sabine Hacker , Stefan Jacobs
IPC: A61K39/395 , A61K47/68 , A61K31/337 , A61K31/5365 , A61K31/7048 , A61K31/7064 , C07K16/28 , G01N33/574 , A61K33/24 , A61N5/10 , C07K16/30 , A61K39/00
Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6, Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.
-
公开(公告)号：US20200031898A1
公开(公告)日：2020-01-30
申请号：US16595440
申请日：2019-10-07
Applicant: BioNTech AG , TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz , Universitatsmedizin der Johannes Gutenberg-Universitat Mainz , JPT Peptide Technologies GmbH
Inventor： Ugur Sahin , Matin Daneschdar , Hans-Ulrich Schmoldt , Laura-Marie Kring (née Plum) , Markus Fiedler , Ulf Reimer , Karsten Schnatbaum
IPC: C07K14/705 , G01N33/53 , A61K39/00 , G01N33/574
Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.
-
公开(公告)号：US10457735B2
公开(公告)日：2019-10-29
申请号：US15538419
申请日：2016-01-08
Applicant: BIONTECH AG , GENMAB A/S
Inventor： Ugur Sahin , Friederike Gieseke , Isil Altintas , David Satijn , Paul Parren
IPC: C07K16/28
Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
-
公开(公告)号：US10370433B2
公开(公告)日：2019-08-06
申请号：US15552215
申请日：2016-03-15
Applicant: BIONTECH AG
Inventor： Ugur Sahin , Joycelyn Wüstehube-Lausch , Markus Fiedler , Matin Daneschdar , Hans-Ulrich Schmoldt
Abstract: The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.
-
Patent Agency Ranking
公开(公告)号：US20190192643A1
公开(公告)日：2019-06-27
申请号：US16229841
申请日：2018-12-21
Applicant: BIONTECH AG , TRON - Translationale Onkologie an der Universitätsmedizin Mainz Gemeinnützige Gmbh
Inventor： Ugur Sahin , Claudia Paret , Kirsten Vormbrock , Christian Bender , Petra Simon , Christoph Hartmann , Stefanie Hubich , Thomas Bukur , Thorsten Litzenberger
IPC: A61K39/00 , C12Q1/6886 , G01N33/574 , C07K14/47
CPC classification number: A61K39/0011 , A61K2039/507 , A61K2039/53 , A61K2039/70 , C07K14/4748 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Q2600/16 , G01N33/57415 , G01N33/57484 , G01N2333/47
Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
-
37.发明授权公开(公告)号：US10106800B2
公开(公告)日：2018-10-23
申请号：US15217555
申请日：2016-07-22
Applicant: BioNTech AG
Inventor： Ugur Sahin , Silke Holtkamp , Ozlem Tureci , Sebastian Kreiter
Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.
-
公开(公告)号：US10093736B2
公开(公告)日：2018-10-09
申请号：US14442445
申请日：2013-11-12
Applicant: Biontech AG , Ganymed Pharmaceuticals AG , TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gemeinnutzige GmbH
Inventor： Ugur Sahin , Ozlem Tureci , Christiane Stadler , Julia Holland , Hayat Bahr-Mahmud , Tim Beissert , Laura Plum , Fabrice Le Gall , Arne Jendretzki , Markus Fiedler
IPC: A61K39/395 , C07K16/28 , C07K16/30 , A61K39/00
Abstract: The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
-
公开(公告)号：US20180037632A1
公开(公告)日：2018-02-08
申请号：US15552215
申请日：2016-03-15
Applicant: BIONTECH AG
Inventor： Ugur Sahin , Joycelyn Wüstehube-Lausch , Markus Fiedler , Matin Daneschdar , Hans-Ulrich Schmoldt
IPC: C07K14/81
CPC classification number: C07K14/811 , C12Y304/21026
Abstract: The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.
-
公开(公告)号：US20170314078A1
公开(公告)日：2017-11-02
申请号：US15591896
申请日：2017-05-10
Applicant: BioNTech AG , Johannes Gutenberg-Universität Mainz
Inventor： Ugur Sahin , Özlem Türeci , Michael Koslowski
CPC classification number: C12Q1/6886 , C07K14/4748 , C07K16/30 , C12Q2600/118 , C12Q2600/158
Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.
-
-
-
-
-
-
-
-
-
Search Results
66
records
(took 0.056 seconds)
